Skip to main content

Micro-tumor Guided Cancer Therapy Selection MicroCaT

Objective

Every year around 350.000 patients in the EU are newly diagnosed with colorectal cancer (CRC). Although € 1.4 Billion are
spent on CRC drugs, the majority of patients fail to respond to therapy because their individual tumor is resistant to the
chosen treatment. These patients suffer from unwanted side effects and after two month are switched to another drug
regime – giving rise to additional drug and hospital costs. 2cureX ApS, a Danish SME, has developed IndiTreat, an ex-vivo
chemosensitivity test. The functional profiling test uses 3D-cellular “micro-tumors” prepared directly from a patient’s tumor. It
allows the selection of the most effective and least toxic drug regimen for each individual patient prior to initiating treatment.
For the oncologists and patients this greatly improves the probability of selecting an effective drug treatment.

The main objective of MicroCaT is to clinically validate the benefits of IndiTreat in an interventional multi-national study with
metastatic (stage IV) colorectal cancer patients. Demonstrating the clinical utility and cost effectiveness of IndiTreat will pave
the way for uptake in EU clinical guidelines and reimbursement arrangements. Communication and dissemination of
MicroCaT project activities will be key to raise the consciousness of this breakthrough innovation with clinicians, patients and
health assessment authorities. Commercializing IndiTreat for CRC patients will enable 2cureX to significantly grow and
expand its business. With the potential to predict therapy responses in all solid forms of cancer, the use of IndiTreat will
eventually result in multi-millions of health care costs savings as well as improving the quality of life of cancer patients across
Europe.

Field of science

  • /social sciences/economics and business
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology
  • /medical and health sciences/clinical medicine/oncology/cancer/colorectal cancer

Call for proposal

H2020-SMEINST-2-2016-2017
See other projects for this call

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

2CUREX A/S
Address
Fruebjergvej 3
2100 Kobenhavn
Denmark
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 2 986 699,25